|
COMMERCE BUSINESS DAILY ISSUE OF APRIL 28,1998 PSA#2083Director, USAMRAA, 820 Chandler St, Fort Detrick, MD 21702-5014 A -- NEUROTOXIN EXPOSURE TREATMENT RESEARCH PROGRAM SOL
CBD&&&-9804-0001 POC CRAIG D. LEBO, Contracting Officer WEB: U.S. Army
Medical Research Acquisition Activity Homepage,
http://www-usamraa.army.mil. E-MAIL: Click here to contact the
Contracting Officer via e-mail., craig_lebo@ftdetrck-ccmail.army.mil.
Neurotoxin Exposure Treatment Research Program The U.S. Army Medical
Research and Materiel Command is soliciting research proposals for
studies on the pathophysiology and treatment of neurodegenerative
diseases, including Parkinson's and Alzheimer's diseases, and including
environmental and stress exposure factors encountered in military
operations which may be neurotoxic or lead to neurodegenerative
conditions. An improved understanding of the pathophysiology of
neurodegenerative diseases will form the basis of potential preventive
measures against the effects of military threat agents and military
operational hazards, and also lead to treatment interventions for
Parkinson's and Alzheimer's diseases. Proposals may be submitted on a
broad range of basic and applied science,including but not limited to
these areas of interest: (1) mechanisms of damage and protection
against neural cell death, including regulation of excitotoxins such as
glutamate, oxidative stress effects, regulation of inflammatory
processes and the protective role of antiinflammatory drugs,
antioxidants, and anticonvulsants, (2) development and validation of
new approaches to neuropsychological testing to improve early detection
of neurodegenerative diseases, (3) new therapeutic strategies for the
treatment of neurodegenerative disease, including neural cell
transplantation, neuroprotection, and alteration of cell biology
through gene-regulation and other novel methods, (4) influence of
environmental factors such as exposure to environmental toxins, toxic
military threat agents, and chronic psychological and physiological
stress in the mediation of neural cell death. Proposals will be
selected for funding on the basis of scientific quality as determined
through an independent scientific peer reviewquality as determined
through an independent scientific peer review and potential military
relevance. Potential application to military populations will be
considered in this award. Projects are typically 2-4 years in duration
and must becompleted by 30 Sep 2004. Program projects will not be
considered. Approximately $20M is available for the lifespan of these
projects. Proposals must be submitted according to general instructions
contained in the Broad Agency Announcement 95-1 (see
http://www-usamraa.army.mil). Letters of intent containing a proposed
title, brief description of project scope (<150 words), and
investigator and institution identification, are requested by 8 July
1998; these are for planning purposes only and investigators will not
receive feedback. Full proposals are due by 4:00 pm EST, Wednesday, 5
August 1998. Send letters of intent and proposals to: Commander, U.S.
Army Medical Research and Materiel Command, ATTN: MCMR-AAA (Neurotox),
Fort Detrick, MD 21702 5014 or electronically to craig_lebo@ftdetrck-
ccmail.army.mil. (0114) Loren Data Corp. http://www.ld.com (SYN# 0008 19980428\A-0008.SOL)
A - Research and Development Index Page
|
|